TOTAL VOLUME:

$134.2b

24H VOL:

$126,324,530

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,434,646,834

406,019

Markets across

30,401

events

MATCHED EVENTS:

2,689

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Tour
All
Sports
Lillestroem vs Egnatia Rrogozhine: First Half Winner
kalshi

Lillestroem vs Egnatia Rrogozhine: First Half Winner

Volume:
$6,198

Egnatia Rrogozhine wins 1st Half

 - Kalshi

Egnatia Rrogozhine wins 1st Half - Kalshi

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Aug 27, 2026

Closed: Aug 27, 1:47 PM EST

kalshi

Kalshi

View
Join Kalshi and score $25 for your first trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
kalshi

Egnatia Rrogozhine wins 1st Half

View
100%
Yes 100¢No 0¢
100¢
N/A
$2,637
N/A
N/A
$2,040
Settled
Yes
kalshi

Tie 1st Half

0%
Yes 0¢No 100¢
100¢
N/A
$2,158
N/A
N/A
$1,854
Settled
No
kalshi

Lillestroem wins 1st Half

0%
Yes 0¢No 100¢
100¢
N/A
$1,403
N/A
N/A
$386
Settled
No
Total markets: 3

Description

This market determines the outcome of the first half of a professional Europa League soccer match between Lillestroem and Egnatia Rrogozhine. Participants can bet on whether a specific team will lead at halftime or if the half will end in a tie, based on the actual game results.

Kalshi

The market resolves based on the first-half result of the Lillestroem vs Egnatia Rrogozhine Europa League match scheduled for August 27, 2026. If Lillestroem scores more goals than Egnatia Rrogozhine in the first 45 minutes plus stoppage time, the 'Lillestroem wins 1st Half' market resolves to Yes. Conversely, if Egnatia Rrogozhine scores more goals, the 'Egnatia Rrogozhine wins 1st Half' market resolves to Yes. Should both teams score an equal number of goals—or no goals at all—the 'Tie 1st Half' market resolves to Yes. If the match is cancelled or postponed by more than 48 hours, all markets will resolve at a fair price as determined by the platform, ensuring equitable treatment for all participants.